Clinical trial
Lower But More Frequent Dose Rituximab to Treat Chronic Lymphocytic Leukemia
NCT00366418 · National Heart, Lung, and Blood Institute (NHLBI), NIH · Completed
Key facts
| NCT number | NCT00366418 |
|---|---|
| Title | Lower But More Frequent Dose Rituximab to Treat Chronic Lymphocytic Leukemia |
| Official title | A Pilot Study of Fractionated Dose Subcutaneous Rituximab (RTX, Rituxan(Registered Trademark)) in Patients With Refractory or Relapsed Chronic Lymphocytic Leukemia |
| Lead sponsor | National Heart, Lung, and Blood Institute (NHLBI), NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Refractory Chronic Lymphocytic Leukemia |
| Intervention type | Drug |
| Interventions | Rituximab |
| Enrollment | 4 |
| Start date | Aug 10, 2006 |
| Primary completion | Jun 11, 2009 |
| Completion | Jun 11, 2009 |
| First posted | Aug 21, 2006 |
| Last update posted | Jul 2, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: